Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Brand-name prescription medicine

Relafen Ds

Generic name: Nabumetone

FDA application holder: LGM Pharma

Official data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the NDC Directory, Drugs@FDA, the official labels and recall reports; pharmacy costs come from the Centers for Medicare & Medicaid Services (CMS). Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or switch any medicine, including a switch between a brand and a generic.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Relafen Ds?
Relafen Ds is a brand name of Nabumetone, a prescription medicine. The FDA NDC Directory lists 1 Relafen Ds product in 1 strength and form.
Who makes Relafen Ds?
LGM Pharma holds the FDA application for Relafen Ds (ANDA203166, approved August 30, 2019).
Is there a generic or store brand of Relafen Ds?
Other products of Nabumetone are listed with the FDA, but none in exactly the same strength and form as a Relafen Ds product.
What do pharmacies pay for Relafen Ds?
CMS lists a National Average Drug Acquisition Cost (NADAC) for 1 Relafen Ds strength and form (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
Has Relafen Ds been recalled?
No recall linked to Relafen Ds products (by their NDC code or label) appears in the FDA enforcement reports we use.

What Relafen Ds is

Each Relafen Ds product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.

Nabumetone · prescription medicine

Strength and formProduct namesSame medicine, other namesLabel
nabumetone 1000 mg
tablet (oral)
Relafen Ds None listed DailyMed

Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Nabumetone →

FDA approval

  • ANDA: Abbreviated New Drug Application: how a generic version is approved.
FDA applications of Relafen Ds products (Drugs@FDA)
ApplicationHolderFirst approvedProducts
ANDA203166LGM PharmaAugust 30, 20191

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Relafen Ds, by strength and form
Strength and formGeneric or brandPharmacies pay
nabumetone 1000 mg
tablet
Brand: Relafen Ds $31.67 per tablet

NADAC list of November 4, 2026; these prices took effect on June 17, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list Relafen Ds

The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Relafen Ds products.

Recalls

No recall linked to Relafen Ds products (by their NDC code or label) appears in the FDA enforcement reports.

Sources

  1. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  2. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026

Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.

Report an error → · Information for medicine makers